Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CN-401 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
CN-401: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EB-DART-NK01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
EB-DART-NK01: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Personalized Neoantigen Peptide Vaccine(Seqker Biosciences) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Personalized Neoantigen Peptide Vaccine(Seqker Biosciences): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
nL-ATN1-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
nL-ATN1-002: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
RLS-1496 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
RLS-1496: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
68Ga-RM26-RGD Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
68Ga-RM26-RGD: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells(Baylor College of Medicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells(Baylor College of Medicine): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
Human adipose derived mesenchymal stem cells (Beijing Aige) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Human adipose derived mesenchymal stem cells (Beijing Aige): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
225Ac-LNC1011 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
225Ac-LNC1011: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
Autologou tumor mRNA transfected dendritic cells (Oslo University Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Autologou tumor mRNA transfected dendritic cells (Oslo University Hospital): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
EcoActive(Intralytix) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
EcoActive(Intralytix): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.